These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35420754)

  • 1. Patients' access to 2018 FDA-approved drugs 1 year post approval.
    Panzer AD; Margaretos NM; Bridger N; Osani MC; Lai RC; Chambers JD
    Am J Manag Care; 2022 Apr; 28(4):e153-e156. PubMed ID: 35420754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
    Panzer AD; Ingham M; Martin S; Chambers JD
    J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
    [No Abstract]   [Full Text] [Related]  

  • 3. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
    Robinson SW; Brantley K; Liow C; Teagarden JR
    J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
    Shaw DL; Dhruva SS; Ross JS
    J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration-expedited programs.
    Jenkins NB; Rucker JA; Klimchak AC; Sedita LE; Chambers JD
    J Manag Care Spec Pharm; 2023 May; 29(5):472-479. PubMed ID: 36864544
    [No Abstract]   [Full Text] [Related]  

  • 6. Coverage of New Drugs in Medicare Part D.
    Naci H; Kyriopoulos I; Feldman WB; Hwang TJ; Kesselheim AS; Chandra A
    Milbank Q; 2022 Jun; 100(2):562-588. PubMed ID: 35502786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients' access to rare neuromuscular disease therapies varies across US private insurers.
    Margaretos NM; Bawa K; Engmann NJ; Chambers JD
    Orphanet J Rare Dis; 2022 Feb; 17(1):36. PubMed ID: 35123543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of prescriber requirements among US commercial health plans.
    Lenahan K; Panzer AD; Gertler R; Chambers JD
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1757-1762. PubMed ID: 34818091
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in access to hemophilia A treatments in the United States.
    Margaretos NM; Patel AM; Panzer AD; Lai RC; Whiteley J; Chambers JD
    J Med Econ; 2021; 24(1):1143-1148. PubMed ID: 34538215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
    Socal MP; Ezebilo I; Bai G; Anderson GF
    Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of orphan drug coverage restrictions in Medicare Part D.
    Yehia F; Segal JB; Anderson GF
    Am J Manag Care; 2020 Sep; 26(9):e289-e294. PubMed ID: 32930558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in US private health plans' coverage of orphan drugs.
    Chambers JD; Panzer AD; Kim DD; Margaretos NM; Neumann PJ
    Am J Manag Care; 2019 Oct; 25(10):508-512. PubMed ID: 31622066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specialty drug coverage varies between health plans' medical and pharmacy benefit policies.
    Levine AA; Panzer AD; Kauf TL; O'Sullivan AK; Strand L; Chambers JD
    J Manag Care Spec Pharm; 2023 Jun; 29(6):607-613. PubMed ID: 37276044
    [No Abstract]   [Full Text] [Related]  

  • 15. Variation in health plan coverage of ESAs for anemia due to chronic kidney disease.
    Margaretos NM; Panzer AD; Lai RC; Sanon M; Michalopoulos E; Redmond AM; Moghadam R; Chambers JD
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1221-1229. PubMed ID: 34464213
    [No Abstract]   [Full Text] [Related]  

  • 16. Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?
    Chambers JD; Margaretos NM; Enright DE; Wang R; Ye X
    Pharmacoeconomics; 2022 Feb; 40(2):225-232. PubMed ID: 34697718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans.
    Yu T; Jin S; Li C; Chambers JD; Hlávka JP
    BioDrugs; 2023 Jul; 37(4):531-540. PubMed ID: 37004706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specialty Drug Coverage Varies Across Commercial Health Plans In The US.
    Chambers JD; Kim DD; Pope EF; Graff JS; Wilkinson CL; Neumann PJ
    Health Aff (Millwood); 2018 Jul; 37(7):1041-1047. PubMed ID: 29985695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in Prescription Drug Coverage for Triptans: Analysis of Insurance Formularies.
    Minen MT; Lindberg K; Langford A; Loder E
    Headache; 2017 Sep; 57(8):1243-1251. PubMed ID: 28691382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. US commercial health plan coverage dynamics in pulmonary arterial hypertension therapies.
    Rucker JA; Beinfeld MT; Enright DE; Germack HD; Panjabi S; Chakinala MM; Chambers JD
    J Manag Care Spec Pharm; 2024 Jun; 30(6):541-548. PubMed ID: 38824632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.